KDOQI对2025年AHA/ACC成人高血压指南的解读
KDOQI专家组针对2025年AHA/ACC成人高血压指南中与CKD风险人群及非透析CKD(1-5期)患者相关的推荐进行解读。新指南正式采用PREVENT计算器整合心血管、肾脏与代谢指标指导风险评估,并强化<130/80 mm Hg的血压目标。工作组总体支持多数推荐,并指出证据有限及CKD管理需额外关注的领域。
要点
- AHA/ACC指南采用PREVENT计算器,整合心血管、肾脏和代谢参数评估风险
- 指南强化<130/80 mm Hg的广泛血压目标,并对复杂和难治性高血压提出推荐
- KDOQI解读聚焦CKD风险人群及非透析CKD 1-5期患者,不涉及维持性透析患者的高血压管理
核心结论
- KDOQI工作组总体支持AHA/ACC指南的多数推荐,并识别出证据有限或CKD管理需额外考虑的领域
研究设计与样本
- KDOQI召开专家组,针对2025年AHA/ACC成人高血压指南中与CKD风险人群及非透析CKD(1-5期)患者相关的推荐进行审查与评论
- 不涵盖维持性透析患者的高血压管理
主要发现
- AHA/ACC指南正式采用PREVENT计算器,整合心血管、肾脏与代谢健康参数指导风险评估与临床决策
- 指南强化<130/80 mm Hg的广泛血压目标,并对复杂和难治性高血压提出推荐
- 对药物相互作用、电解质紊乱和肾损伤等指南未给出正式推荐的领域,工作组提供专家评论
关键数值与推荐
- AHA/ACC指南推荐广泛血压目标为<130/80 mm Hg
- 指南采用PREVENT计算器整合心血管、肾脏与代谢健康参数进行风险评估
临床怎么用
- 临床上可将PREVENT计算器纳入CKD患者心血管风险预测
- 对复杂和难治性高血压患者参照AHA/ACC推荐管理
- 对药物相互作用、电解质紊乱和肾损伤等问题,参考KDOQI专家评论并结合CKD情况个体化管理
局限性
- AHA/ACC指南未对药物相互作用、电解质紊乱和肾损伤等领域提供正式推荐
- 部分推荐证据仍有限,CKD管理需额外考虑
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension prevention, diagnosis, and management are central to modifying the progression of chronic kidney disease (CKD). Although the nephrology community has long recognized CKD as an independent risk factor for cardiovascular disease, CKD has not historically been incorporated in cardiovascular risk prediction models. The new 2025 American Heart Association and American College of Cardiology (AHA/ACC) Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults addresses this gap by formally adopting the PREVENT calculator, which combines cardiovascular, kidney, and metabolic health parameters to guide risk assessment and clinical decision making. The AHA/ACC guideline reinforces the broad blood pressure target of <130/80 mm Hg as well as makes recommendations for complex and resistant hypertension. Given the impact of these recommendations on persons living with kidney disease, the Kidney Disease Outcomes Quality Initiative (KDOQI) convened an expert work group to review and comment on the guideline. This KDOQI commentary focuses on recommendations from the AHA/ACC guideline that are pertinent to individuals at risk of CKD or with non-dialysis-dependent CKD (stages 1-5), hence excluding commentary on hypertension management in patients receiving maintenance dialysis. In areas where the AHA/ACC guideline does not offer formal recommendations (eg, medication interactions, electrolyte imbalances, and kidney injury), the work group provides expert commentary about implications for people with CKD. Overall, the work group supports the majority of the AHA/ACC recommendations and identifies areas where evidence remains limited or management in CKD warrants additional consideration.
引用
- Chang TI, Cluett JL, Cohen DL, et al. KDOQI Commentary on the 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Kidney Dis. 2026. PMID: 42907045. doi:10.1053/j.ajkd.2026.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。